Finally, we demonstrate that the investigated MIR149, MIR605, MIR938, DROSHA, MIR200C, MIR499A, MIRLET7A1, MIR323B, and MIR2053 could potentially modulate the therapeutic response of standard treatment for ALL. Here, MIR2053 is linked to acute lymphoblastic leukemia.